Eisai Files Alzheimer’s Drug Lecanemab In Europe But Will EMA Grant Fast Track?
Accelerated Assessment Could Cut Months Off Review
Eisai and Biogen’s aducanumab was never approved in the European Union and while lecanemab is generating more confidence, a fast track review has not yet been confirmed.
